In October 2007, Galapagos announced a multi-target alliance with Janssen Pharmaceutica NV, a Johnson & Johnson company, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis. Galapagos is responsible for the discovery and development of drug candidates through to clinical Proof of Concept, at which point Janssen will have an exclusive option to license each compound for further development and commercialization on a worldwide basis.
One of the programs in the alliance includes a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine. Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule that enters the clinic for inflammatory disorders like inflammatory bowel disease. Galapagos will be responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.
The aim of this FIH study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205. The randomized, double-blind, placebo-controlled, single center study will be conducted in 40 healthy volunteers in Belgium. In the first part of the study, single ascending doses will be evaluated. In the second part, the new compound will be administered daily for 14 days. Galapagos expects to disclose topline results from the study by the end of this year.